The US Centers for Medicare and Medicaid Services (CMS) said on 29 April that it is considering reimbursement of next-generation sequencing tests that can pinpoint cancer-causing germline mutations in a beneficiary and help provide personalized therapies to treat cancers.
“It is important that tests detect somatic (cancer) and germline (inherited) mutations accurately and produce valid results that are useful...